tbuckley/cabot-search huggingface dataset:
Cytoreductive nephrectomy in the United States: Patterns of care and patient characteristics.
Authors: Che-Kai Tsao, Erin Moshier, Alexander C. Small, Guru Sonpavde, James Godbold, William K. Oh, Matt D. Galsky
Journal: Journal of Clinical Oncology (2012)

366 Background: Two randomized trials published in 2001 established cytoreductive nephrectomy (CyNx) for patients (pts) with metastatic renal carcinoma (mRCC) as a treatment standard in the cytokine era (Flanigan, J Urol, 2004). However, first-line systemic therapy for mRCC changed in 2005 with FDA approval of VEGFR tyrosine kinase inhibitor (TKIs). We evaluated the patterns of use of CyNx in the pre- and post-TKI era and characteristics of pts undergoing CyNx. Methods: The National Cancer Database was queried for pts diagnosed with mRCC between 2000 and 2008. Pts who underwent CyNx were identified and were further categorized by pre- versus post-TKI era (2000–2006 vs. 2006–2008), race, insurance status, and hospital. For these subcategories, prevalence ratios (PR) were generated using the proportion of pts with mRCC undergoing CyNx versus those not undergoing CyNx. Results: Of the 47,417 patients (pts) with mRCC diagnosed between 2000 and 2008, 25,616 pts (54%) did not undergo CyNx. The prevalence of cytoreductive nephrectomy increased 3% each year from 2000 to 2006 (p&lt;0.0001), then decreased 3% each year from 2006 to 2008 (p=0.0048), with a significant difference between the pre- and post-2006 PR (0.97 versus 1.025; p&lt;0.0001). Blacks (PR 1.17) and Hispanics (PR 1.05) were significantly more likely than Caucasian to not undergo CyNx (p&lt;0.008). Pts with Medicaid (PR 1.25), Medicare (PR 1.40), and no insurance (PR 1.42) were significantly more likely than pts with private insurance to not undergo CyNx (p&lt;0.0001). Pts diagnosed at community hospitals (PR 1.29) were significantly more likely than pts at teaching hospitals to not undergo CyNx (p &lt;0.0001). Conclusions: The use of CyNx has declined in the post-TKI era. In addition, racial and socioeconomic disparities exist in the use of CyNx. The results of pending randomized trials evaluating the role of CyNx in the post-TKI era are awaited to optimize use of this modality.
Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity
Authors: Agrin Moeini, Daniela Sia, Zhongyang Zhang, Genis Camprecios, Ashley Stueck, Hui Dong, Robert Montal, Laura Torrens, Iris Martinez-Quetglas, M. Isabel Fiel, Ke Hao, Augusto Villanueva, Swan N. Thung, Myron E. Schwartz, Josep M. Llovet
Journal: Journal of Hepatology (2017)
Nail apparatus melanoma thickness is associated with side and age
Authors: A. Minagawa, T. Omodaka, H. Koga, Y. Yokokawa, H. Uhara, R. Okuyama
Journal: British Journal of Dermatology (2017)

Nail apparatus melanoma (NAM) is a rare variant of cutaneous melanoma that arises in the nail unit and typically appears as melanonychia in its early stage.1 Since the factors associated with the progression of NAM are not fully understood, 102 cases of NAM were analysed to identify clinical factors associated with Breslow's thickness.

This article is protected by copyright. All rights reserved.
A Look at Republican Plans for Repealing and Replacing Obamacare
Authors: Aaron E. Carroll
Journal: JAMA (2017)

on standby whenever patients with PD need them.Tolani is planning a trip to Asia, and he's concerned about how he'll do without his dance classes.He plans to ask Leventhal to borrow a Glass so he can use the app while he's away."With this PD condition, it becomes very comfortable to become isolated and not say or do anything because you struggle so much with speech and everything else, which is so discouraging," Tolani
Modest Prolongation of Survival for Patients 60-80 Year at Time of Acute Myelogenous Leukemia (AML) Diagnosis Who Are Treated with Conventional AML Therapy: A Provincial Cohort Analysis.
Authors: Maneesh Sud, Demers Alain, Rajat Kumar, Grace Musto, Matthew D. Seftel, Erin Richardson, Morel Rubinger, Brent Allan Schacter, Donna A. Wall, David Szwajcer
Journal: Blood (2009)
Autophagy Is a Relevant Cellular Process In CLL and Contributes to Drug Resistance of Flavopiridol
Authors: Emilia Mahoney, Amy J. Johnson, Amy J. Wagner, Joshua Hessler, Sneha V. Gupta, Sarah E.M. Herman, Leslie Andritsos, Jeffrey A. Jones, Joseph M. Flynn, David M. Lucas, Michael R. Grever, John C. Byrd
Journal: Blood (2010)
Associations of Antifungal Treatments With Prevention of Fungal Infection in Critically Ill Patients Without Neutropenia
Authors: Andrea Cortegiani, Vincenzo Russotto, Antonino Giarratano
Journal: JAMA (2017)

<h3>Clinical Question</h3> Are antifungal agents associated with lower rates of mortality and invasive fungal infections when administered before definitive diagnosis of an invasive fungal infection in critically ill patients without neutropenia? <h3>Bottom Line</h3> Antifungal treatment administered prior to diagnosis of an invasive fungal infection is not associated with either higher or lower rates of all-cause mortality. Antifungal treatment in this setting is associated with lower rates of invasive fungal infections compared with placebo or no intervention in critically ill patients without neutropenia, but the quality of the evidence is low.
Integrin αIIbβ3-Mediated Outside-in Signaling: Brake or Amplifier of Platelet Activation?
Authors: Baiyun Dai, Peng Wu, Feng Xue, Renchi Yang, Ziqiang Yu, Kesheng Dai, Changgeng Ruan, Jieqing Zhu, Peter J. Newman, Cunji Gao
Journal: Blood (2014)
Prognostic Models to Predict Survival In Indolent and Aggressive Non-Hodgkin's Lymphomas Associated with Hepatitis C Virus Infection: a Multicenter Italian Study on 1,043 Patients.
Authors: Michele Merli, Michele Spina, Stefano Luminari, Claudia Basilico, Clara Targhetta, Carlo Visco, Alessandro Levis, Davide Rossi, Alfonso Maria D'Arco, Luigi Rigacci, Achille Ambrosetti, Pellegrino Musto, Alessandra Tucci, Annalisa Chiappella, Andrea Ferrario, Sara Rattotti, Virginia Valeria Ferretti, Cristiana Pascutto, Luca Arcaini
Journal: Blood (2010)
Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk
Authors: Helen R Warren, Evangelos Evangelou, Claudia P Cabrera, He Gao, Meixia Ren, Borbala Mifsud, Ioanna Ntalla, Praveen Surendran, Chunyu Liu, James P Cook, Aldi T Kraja, Fotios Drenos, Marie Loh, Niek Verweij, Jonathan Marten, Ibrahim Karaman, Marcelo P Segura Lepe, Paul F O'Reilly, Joanne Knight, Harold Snieder, Norihiro Kato, Jiang He, E Shyong Tai, M Abdullah Said, David Porteous, Maris Alver, Neil Poulter, Martin Farrall, Ron T Gansevoort, Sandosh Padmanabhan, Reedik Mägi, Alice Stanton, John Connell, Stephan J L Bakker, Andres Metspalu, Denis C Shields, Simon Thom, Morris Brown, Peter Sever, Tõnu Esko, Caroline Hayward, Pim van der Harst, Danish Saleheen, Rajiv Chowdhury, John C Chambers, Daniel I Chasman, Aravinda Chakravarti, Christopher Newton-Cheh, Cecilia M Lindgren, Daniel Levy, Jaspal S Kooner, Bernard Keavney, Maciej Tomaszewski, Nilesh J Samani, Joanna M M Howson, Martin D Tobin, Patricia B Munroe, Georg B Ehret, Louise V Wain
Journal: Nature Genetics (2017)
Targeting Brouton's Tyrosine Kinase with PCI-32765 Blocks Growth and Survival of Multiple Myeloma and Waldenström Macroglobulinemia Via Potent Inhibition of Osteoclastogenesis, Cytokines/Chemokine Secretion, and Myeloma Stem-Like Cells in the Bone Marrow Microenvironment
Authors: Yu-Tzu Tai, Betty Y Chang, Sun-Young Kong, Mariateresa Fulciniti, Guang Yang, Yolanda Calle, Yiguo Hu, Jianhong Lin, Jian-Jun Zhao, Michele Cea, Antonia Cagnetta, Michael A Sellitto, Michelle Chen, Zachary Hunter, Ruben Carrasco, Joseph J. Buggy, Laurence Elias, William Matsui, Steven P Treon, Paul G. Richardson, Nikhil C. Munshi, Kenneth C. Anderson
Journal: Blood (2011)
ATCT-31CENTRAL RADIOLOGY REVIEW OF THE BELOB TRIAL: TREATMENT WITH BEVACIZUMAB IN RECURRENT GLIOBLASTOMA IS ASSOCIATED WITH MORE FREQUENT NON-ENHANCING PROGRESSION
Authors: Marion Smits, Linda Bralten, Bas Jasperse, Walter Taal, Renske Gahrmann, Annemiek Walenkamp, Rianne Oosterkamp, Rene Vernhout, Bronno van der Holt, Martin van den Bent
Journal: Neuro-Oncology (2015)

INTRODUCTION: Central radiology review may change both response rates and progression free survival (PFS). Bevacizumab treatment of recurrent glioblastoma has been associated with increased progression on T2/FLAIR images only and a different pattern of progression. We centrally reviewed the responses obtained within the prospective randomized BELOB trial and examined the pattern of progression. METHODS: Patients treated within the BELOB trial underwent MR disease assessment every 6 weeks within the first 6 months, thereafter every 12 weeks. Response was assessed using the RANO criteria, the protocol did not require response confirmation after 4 weeks. Two independent reviewers re-assessed all responses (ORR) and dates of progression; in case of disagreement a third reviewer served as the adjudicator. To define the pattern of progression we distinguished between local/distant/diffuse/multifocal progression according to Pope et al (Neurology 2011;76:432-7). RESULTS: For 137 patients central review of response was possible. Agreement between the two central reviewers and between the definitive central and local response was modest (kappa 0.60 and 0.54 respectively). The 6mo PFS rate at central review was similar to the local analysis. In 115 patients the pattern of progression could be assessed. Of 76 patients treated with bevacizumab (with or without lomustine) 13 had T2 progression only, as opposed to only 1 out of 39 lomustine monotherapy patients (p = 0.032). T2 mass progression only was observed in 8:76 bevacizumab treated patients vs 0:39 lomustine monotherapy patients ( p = 0.0497). Treatment with bevacizumab did not result in more multifocal or diffuse relapses. CONCLUSION: Despite interobserver variation at the patient level, at the trial level both ORR and 6 mo PFS outcome of the BELOB remained the same after central review. In the BELOB trial bevacizumab was associated with progression limited to increased T2/FLAIR abnormalities, but not with a different pattern of progression.
Persistence of psychosis spectrum symptoms in the Philadelphia Neurodevelopmental Cohort: a prospective two‐year follow‐up
Authors: Monica E. Calkins, Tyler M. Moore, Theodore D. Satterthwaite, Daniel H. Wolf, Bruce I. Turetsky, David R. Roalf, Kathleen R. Merikangas, Kosha Ruparel, Christian G. Kohler, Ruben C. Gur, Raquel E. Gur
Journal: World Psychiatry (2017)

Prospective evaluation of youths with early psychotic-like experiences can enrich our knowledge of clinical, biobehavioral and environmental risk and protective factors associated with the development of psychotic disorders. We aimed to investigate the predictors of persistence or worsening of psychosis spectrum features among US youth through the first large systematic study to evaluate subclinical symptoms in the community. Based on Time 1 screen of 9,498 youth (age 8-21) from the Philadelphia Neurodevelopmental Cohort, a subsample of participants was enrolled based on the presence (N=249) or absence (N=254) of baseline psychosis spectrum symptoms, prior participation in neuroimaging, and current neuroimaging eligibility. They were invited to participate in a Time 2 assessment two years on average following Time 1. Participants were administered the Structured Interview for Prodromal Syndromes, conducted blind to initial screen status, along with the Schizotypal Personality Questionnaire and other clinical measures, computerized neurocognitive testing, and neuroimaging. Clinical and demographic predictors of symptom persistence were examined using logistic regression. At Time 2, psychosis spectrum features persisted or worsened in 51.4% of youths. Symptom persistence was predicted by higher severity of subclinical psychosis, lower global functioning, and prior psychiatric medication at baseline. Youths classified as having psychosis spectrum symptoms at baseline but not at follow-up nonetheless exhibited comparatively higher symptom levels and lower functioning at both baseline and follow-up than typically developing youths. In addition, psychosis spectrum features emerged in a small number of young people who previously had not reported significant symptoms but who had exhibited early clinical warning signs. Together, our findings indicate that varying courses of psychosis spectrum symptoms are evident early in US youth, supporting the importance of investigating psychosis risk as a dynamic developmental process. Neurocognition, brain structure and function, and genomics may be integrated with clinical data to provide early indices of symptom persistence and worsening in youths at risk for psychosis.
Multiple Myeloma (MM) Highly Expresses CGEN-928 and the Anti-CGEN-928 TM21 Antibody Markedly Inhibits the Growth of MM Cells and Enhances the Anti-Myeloma Effects of Dexamethasone, Melphalan and Bortezomib
Authors: Haiming Chen, Mingjie Li, Cathy Wang, Jessica Wang, Eric Sanchez, Zhi-Wei Li, Benjamin Bonavida, Ofer Levy, Liat Dassa, Gady Cojocaru, James R. Berenson, Zurit Levine
Journal: Blood (2010)
Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis.
Authors: P H Nachman, S L Hogan, J C Jennette, R J Falk
Journal: Journal of the American Society of Nephrology (1996)

In this study, the rate of remission, relapse, and treatment resistance in 107 patients with microscopic polyangiitis and necrotizing and crescentic glomerulonephritis associated with antineutrophil cytoplasmic autoantibodies were assessed. Patients with Wegener's granulomatosis were excluded. Prospective criteria were identified to assess remission, relapse, and resistant disease. Ninety-seven of the 107 patients received treatment with corticosteroids (N = 25) or with cyclophosphamide and corticosteroids (N = 72). Of these patients, 75 (77.3%) went into remission (complete remission, N = 61; remission on therapy, N = 14). Of the 75 responders, 32 patients (43%) remained in long-term remission, for a mean follow-up of 44 +/- 29 months; 15 patients (20%) progressed to ESRD without signs of relapse, for a mean of 21.4 +/- 22.8 months after the end of treatment; 6 patients died. Twenty-two of the 75 patients who initially responded to treatment (29%) suffered a relapse that occurred within 18 months of the end of therapy and usually affected the same organ systems as on initial presentation. There was a significant difference in the remission rate between the corticosteroid-treated patients and the cyclophosphamide-treated patients (56% versus 84.7%, P = 0.003), and the cyclophosphamide-treated patients had three times less risk of experiencing a relapse than did corticosteroid-treated patients (0.31, 95% Cl = (0.12, 0.84)). Seventy-seven percent (17 of 22 patients) of treatment resistance occurred in patients who presented with fulminant disease or advanced and severe renal disease. It was concluded that most patients with microscopic polyangiitis or necrotizing and crescentic glomerulonephritis achieve remission with therapy. Relapses occur in 29% of patients and generally respond to retreatment. Initial treatment with cyclophosphamide and corticosteroids rather than corticosteroids alone results in a lower frequency of relapse. Even patients who require dialysis at presentation may benefit from treatment, however, patients who are not treated until the disease process is life-threatening may die before induction therapy is complete, indicating the continued need for early diagnosis and therapy.
Geographical Variation Shows Differences in Disease Characteristics Among Patients with Multiple Myeloma.
Authors: Sikander Ailawadhi, Michael Keng, Ann Mohrbacher, Eddie Thara, Dongyun Yang, Taimur Sher, Mehul P Patel, Kena C Miller, Susan Groshen, Asher A. Chanan-Khan
Journal: Blood (2009)
The Roles of Wilms’ Tumor Gene Peptide-Specific Cytotoxic T Lymphocytes in Immunologic Pathophysiology of Paroxysmal Nocturnal Hemoglobinuria.
Authors: Kazuhiko Ikeda, Hideyoshi Noji, Masaki Yasukawa, Akiko Shichishima, Kazuko Akutsu, Yukio Maruyama, Tsutomu Shichishima
Journal: Blood (2007)
Superior Long Term Progression Free Survival of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Compared to Autologous Hematopoietic Stem Cell Transplantation after Identical Conditioning Regimen.
Authors: Yasser Khaled, Koji Kato, John E. Levine, Smitha Mellacheruvu, Andrzej Jakubowiak, Oleg Krijanovski, Edward Peres, Pavan Reddy, Kevin Knott, Greg Yanik, James Ferrara, Shin Mineishi
Journal: Blood (2007)
Highest Blood Pressure Levels Shift From Rich to Poor Countries
Authors: M.J. Friedrich
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Successful endoscopic closure of iatrogenic duodenal perforation with the new Padlock Clip
Authors: Andrea Anderloni, Mario Bianchetti, Benedetto Mangiavillano, Alessandro Fugazza, Milena Di Leo, Silvia Carrara, Alessandro Repici
Journal: Endoscopy (2017)

Although duodenal perforations are rare [1], they represent one of the most critical complications of endoscopic ultrasound (EUS) and may be fatal in elderly patients. Following the introduction of endoscopic clips, stents, and over-the-scope systems into clinical practice, endoscopic management of perforations has became the first therapeutic option [2] [3].
DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma
Authors: Nathan C Sheffield, Gaelle Pierron, Johanna Klughammer, Paul Datlinger, Andreas Schönegger, Michael Schuster, Johanna Hadler, Didier Surdez, Delphine Guillemot, Eve Lapouble, Paul Freneaux, Jacqueline Champigneulle, Raymonde Bouvier, Diana Walder, Ingeborg M Ambros, Caroline Hutter, Eva Sorz, Ana T Amaral, Enrique de Álava, Katharina Schallmoser, Dirk Strunk, Beate Rinner, Bernadette Liegl-Atzwanger, Berthold Huppertz, Andreas Leithner, Gonzague de Pinieux, Philippe Terrier, Valérie Laurence, Jean Michon, Ruth Ladenstein, Wolfgang Holter, Reinhard Windhager, Uta Dirksen, Peter F Ambros, Olivier Delattre, Heinrich Kovar, Christoph Bock, Eleni M Tomazou
Journal: Nature Medicine (2017)
Efficacy and Safety of Once Weekly Epoetin Beta 30 000 IU in 691 Patients with Solid or Lymphoid Malignancies Receiving Chemotherapy: Results from the NAUTICA Study.
Authors: Dominique Spaeth, Gilles Salles, Thierry Facon, Reda Garidi, Francois Pichon, Ghandi Damaj, Loic Bergougnoux
Journal: Blood (2006)
Dual delivery of growth factors with coacervate-coated poly(lactic-co-glycolic acid) nanofiber improves neovascularization in a mouse skin flap model
Authors: Min Suk Lee, Taufiq Ahmad, Jinkyu Lee, Hassan K. Awada, Yadong Wang, Kyobum Kim, Heungsoo Shin, Hee Seok Yang
Journal: Biomaterials (2017)
SH2-Containing-5′Inositol Phosphatase-1 (SHIP) Regulates Megakaryocytic Progenitors Numbers (MKP) and Determines Megakaryocyte (MK) In Vivo Localization.
Authors: Lia E. Perez, Caroline Desponts, Nancy Parquet, William G. Kerr
Journal: Blood (2004)
Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party
Authors: Marie Thérèse Rubio, Maud D’Aveni-Piney, Myriam Labopin, Rose-Marie Hamladji, Miguel A. Sanz, Didier Blaise, Hakan Ozdogu, Etienne Daguindeau, Carlos Richard, Stella Santarone, Giuseppe Irrera, Ibrahim Yakoub-Agha, Moshe Yeshurun, Jose L. Diez-Martin, Mohamad Mohty, Bipin N Savani, Arnon Nagler
Journal: Journal of Hematology & Oncology (2017)

The impact of the use of anti-thymocyte globulin (ATG) in allogeneic stem cell transplantation performed with HLA-identical sibling donors following fludarabine and 4 days intravenous busulfan myeloablative conditioning regimen has been poorly explored.We retrospectively analyzed 566 patients who underwent a first HLA-identical allogeneic stem cell transplantation with this conditioning regimen for acute myeloid leukemia in first complete remission between 2006 and 2013 and compared the outcomes of 145 (25.6%) patients who received ATG (ATG group) to 421 (74.4%) who did not (no-ATG group). The Kaplan-Meier estimator, the cumulative incidence function, and Cox proportional hazards regression models were used where appropriate.Patients in the ATG group were older, received more frequently peripheral blood stem cell grafts from older donors, and were transplanted more recently. With a median follow-up of 19 months, patients in the ATG group had reduced 2-year cumulative incidence of chronic graft-versus-host disease (GVHD) (31 vs. 52%, p = 0.0002) and of its extensive form (8 vs. 26%, p < 0.0001) but similar relapse incidence (22 vs. 27%, p = 0.23) leading to improved GVHD and relapse-free survival (GRFS) (60 vs. 40%, p = 0.0001). In multivariate analyses, the addition of ATG was independently associated with lower chronic GVHD (HR = 0.46, p = 0.0001), improved leukemia-free survival (HR = 0.67, p = 0.027), overall survival (HR = 0.65, p = 0.027), and GRFS (HR = 0.51, p = 4 × 10-5). Recipient age above 50 years was the only other factor associated with worse survivals.These results suggest that the use of ATG with fludarabine and 4 days intravenous busulfan followed by HLA-identical sibling donor allogeneic stem cell transplantation for acute myeloid leukemia improves overall transplant outcomes due to reduced incidence of chronic GVHD without increased relapse risk.
Targeting <i>Staphylococcus aureus</i> in Pediatric Surviving Sepsis Bundles—Reply
Authors: Brendan J. McMullan, Asha C. Bowen, Steven Y. C. Tong
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal